Spreading assays were performed using duplicate determinations, as described previously.
17 Before replating onto coverslips precoated with 20 nM fibronectin, suspended cells were preincubated for 30 to 60 minutes in the absence or presence of 0.25, 1, 5, or 20 μM of the Src family kinase (SFK) inhibitor PP2 (EMD Biosciences, Inc., San Diego, CA), 60 μM of the selective SFK inhibitor
cis-5,8,11,14,17-eicosapentaenoic acid (EPA, Sigma), 20 μM of the PI-3K inhibitor LY294002 (EMD Bioscience, Inc.), 20 μM of the Rac1 inhibitor NSC23766
40 (kindly provided by Yi Zheng, Children's Hospital Research Foundation, Cincinnati, OH), or 100 nM of the dominant negative (DN) form of the Rac1 guanine nucleotide exchange factor (GEF) Tiam1. Cells pretreated with dimethyl sulfoxide (DMSO) were used as controls for PP2, EPA, and LY294002 treatments. Treated cells were then plated in the absence or presence of 8 μg/mL mAb AP-5, which activates β3 integrins. In some experiments, cells were plated in the presence of 100 or 200 μg/mL CD47 agonist peptide 4N1K (KRFYVVMWKK) derived from the carboxyl-terminal domain of TSP1,
27 200 μg/mL control peptide 4NGG (KRFYGGMWKK), or 20 μg/mL CD47 function blocking mAb B6H12.2 (Abcam, Inc., Cambridge, MA). All cells were allowed to spread for 3 hours and then were fixed with 4%
p-formaldehyde plus 0.18% Triton X-100 for 30 minutes. Human plasma fibronectin was prepared as described.
41